Intra-Cellular Therapies, Inc.
ORGANIC COMPOUNDS
Last updated:
Abstract:
The present invention relates to novel compounds having a capacity for PDE1 inhibition which may be used as tracers for use in diagnostic techniques, biomarkers for phosphodiesterase 1 (PDE1) in vivo, methods for treating and/or developing novel therapies for PDE1-associated conditions, and to methods of detection and treatment.
Status:
Application
Type:
Utility
Filling date:
10 Apr 2020
Issue date:
16 Jun 2022